Imugene Ltd (ASX:IMU, OTC:IUGNF) has presented new and first data from the Phase 1 CHECKVacc trial at the 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas.
The presentation, titled “Phase 1 study of intratumoral administration of CF33-hNIS-antiPD-L1 (CHECKvacc) in patients with metastatic triple negative breast cancer”, was presented by Dr Yuan Yuan M.D., PhD, Cedars Sinai Medicine, Los Angeles and Dr Jamie Rand M.D., City of Hope, Los Angeles.
Notably, Imugene has observed that CHECKvacc administered by intratumoral injection in patients with metastatic triple negative breast cancer (TNBC) is safe and well tolerated at the dose levels tested.
Seeing positive signals
Imugene MD and CEO Leslie Chong said: “Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development.
“I am encouraged that we are seeing positive signals with correlative biomarker and imaging data at such an early stage of our CHECKVacc Phase I trial.”
About CHECKvacc
CF33-hNIS-antiPDL1 or CHECKvacc is an immune checkpoint inhibitor armed with chimeric vaccinia poxvirus.
It is being developed at the lab of CF33 inventor Professor Yuman Fong, chair of the Sangiacomo family chair in surgical oncology at City of Hope, one of the largest cancer research and treatment organisations in the United States, and a noted expert in the oncolytic virus field.
Oncolytic viruses (OVs) are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.